Lonafarnib for cancer and progeria

Bibliography

• Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343(6257):425-30
   PubMed Web of Science ®Google Scholar
• Lobell RB. Prenylation of Ras GTPase superfamily proteins and their function in immunobiology. Adv Immunol 1998;68:145-89
   PubMed Web of Science ®Google Scholar
• Schafer WR, Trueblood CE, Yang CC, Enzymatic coupling of cholesterol intermediates to a mating pheromone precursor and to the ras protein. Science 1990;249(4973):1133-9
   PubMed Web of Science ®Google Scholar
• Sebti SM. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell 2005;7(4):297-300
   PubMed Web of Science ®Google Scholar
• Casey PJ, Solski PA, Der CJ, Buss JE. p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 1989;86(21):8323-7
   PubMed Web of Science ®Google Scholar
• Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001;81(1):153-208
   PubMed Web of Science ®Google Scholar
• Gille H, Downward J. Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem 1999;274(31):22033-40
   PubMed Web of Science ®Google Scholar
• Katso R, Okkenhaug K, Ahmadi K, Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001;17:615-75
   PubMed Web of Science ®Google Scholar
• Lambert JM, Lambert QT, Reuther GW, Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat Cell Biol 2002;4(8):621-5
   PubMed Web of Science ®Google Scholar
• Ferro E, Trabalzini L. RalGDS family members couple Ras to Ral signalling and that's not all. Cell Signal 2010;22(12):1804-10
   PubMed Web of Science ®Google Scholar
• Yan M, Dai T, Deak JC, Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 1994;372(6508):798-800
   PubMed Web of Science ®Google Scholar
• Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49(17):4682-9
   PubMed Web of Science ®Google Scholar
• Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93(14):1062-74
   PubMed Web of Science ®Google Scholar
• Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000;96(5):1655-69; 31
   PubMed Web of Science ®Google Scholar
• Mijimolle N, Velasco J, Dubus P, Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell 2005;7(4):313-24
   PubMed Web of Science ®Google Scholar
• Sepp-Lorenzino L, Ma Z, Rands E, A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 1995;55:5302-9
   PubMed Web of Science ®Google Scholar
• Sun J, Qian Y, Hamilton AD, Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 1998;16:1467-73
   PubMed Web of Science ®Google Scholar
• James GL, Goldstein JL, Brown MS. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 1995;270(11):6221-6
   PubMed Web of Science ®Google Scholar
• Lerner EC, Zhang TT, Knowles DB, Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 1997;15(11):1283-8
   PubMed Web of Science ®Google Scholar
• Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J Biol Chem 1997;272(22):14093-7
   PubMed Web of Science ®Google Scholar
• Whyte DB, Kirschmeier P, Hockenberry TN, K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997;272(22):14459-64
   PubMed Web of Science ®Google Scholar
• Gruenbaum Y, Margalit A, Goldman RD, The nuclear lamina comes of age. Nat Rev Mol Cell Biol 2005;6(1):21-31
   PubMed Web of Science ®Google Scholar
• Eriksson M, Brown WT, Gordon LB, Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003;423(6937):293-8
   PubMed Web of Science ®Google Scholar
• De Sandre-Giovannoli A, Bernard R, Cau P, Lamin a truncation in Hutchinson-Gilford progeria. Science 2003;300(5628):2055
   PubMed Web of Science ®Google Scholar
• Goldman RD, Shumaker DK, Erdos MR, Accumulation of mutant lamin a causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2004;101(24):8963-8
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T. Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 2005;11(4):440-5
   PubMed Web of Science ®Google Scholar
• Marji J, O'Donoghue SI, McClintock D, Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition. PLoS One 2010;5(6):e11132
   PubMedGoogle Scholar
• Leonard DM. Ras farnesyltransferase: a new therapeutic target. J Med Chem 1997;40(19):2971-90
   PubMed Web of Science ®Google Scholar
• Sparano JA, Moulder S, Kazi A, Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res 2009;15(8):2942-8
   PubMed Web of Science ®Google Scholar
• Johnston SR, Hickish T, Ellis P, Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003;21(13):2492-9
   PubMed Web of Science ®Google Scholar
• Lancet JE, Gojo I, Gotlib J, A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2007;109(4):1387-94
   PubMed Web of Science ®Google Scholar
• Fenaux P, Raza A, Mufti GJ, A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 2007;109(10):4158-63
   PubMed Web of Science ®Google Scholar
• Ryan DP, Eder JP Jr, Puchlaski T, Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin Cancer Res 2004;10(7):2222-30
   PubMed Web of Science ®Google Scholar
• Mackay HJ, Hoekstra R, Eskens FA, A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors. Clin Cancer Res 2004;10(8):2636-44
   PubMed Web of Science ®Google Scholar
• Bailey HH, Alberti DB, Thomas JP, Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. Clin Cancer Res 2007;13(12):3623-9
   PubMed Web of Science ®Google Scholar
• Dy GK, Adjei AA. Farnesyltransferase inhibitors in breast cancer therapy. Cancer Invest 2002;20(Suppl 2):30-7
   PubMedGoogle Scholar
• Moulder SL, Mahany JJ, Lush R, A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors. Clin Cancer Res 2004;10(21):7127-35
   PubMed Web of Science ®Google Scholar
• Appels NM, Bolijn MJ, Chan K, Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer. Br J Cancer 2008;98(12):1951-8
   PubMed Web of Science ®Google Scholar
• Adjei AA, Erlichman C, Davis JN, A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 2000;60(7):1871-7
   PubMed Web of Science ®Google Scholar
• Liu M, Bryant MS, Chen J, Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 1998;58(21):4947-56
   PubMed Web of Science ®Google Scholar
• Feldkamp MM, Lau N, Roncari L, Guha A. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res 2001;61(11):4425-31
   PubMed Web of Science ®Google Scholar
• Smalley KS, Eisen TG. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer 2003;105(2):165-75
   PubMed Web of Science ®Google Scholar
• Sun SY, Liu X, Zou W, The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells. J Biol Chem 2007;282(26):18800-9
   PubMed Web of Science ®Google Scholar
• Ashar HR, James L, Gray K, The farnesyl transferase inhibitor SCH 66336 induces a G(2) –> M or G(1) pause in sensitive human tumor cell lines. Exp Cell Res 2001;262(1):17-27
   PubMed Web of Science ®Google Scholar
• Adjei AA, Davis JN, Bruzek LM, Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 2001;7(5):1438-45
   PubMed Web of Science ®Google Scholar
• Shi B, Yaremko B, Hajian G, The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 2000;46(5):387-93
   PubMed Web of Science ®Google Scholar
• Taylor SA, Marrinan CH, Liu G, Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo. Gynecol Oncol 2008;109(1):97-106
   PubMed Web of Science ®Google Scholar
• Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002;100(3):1068-71
   PubMed Web of Science ®Google Scholar
• Nakajima A, Tauchi T, Sumi M, Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Mol Cancer Ther 2003;2(3):219-24
   PubMed Web of Science ®Google Scholar
• Peters DG, Hoover RR, Gerlach MJ, Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood 2001;97(5):1404-12
   PubMed Web of Science ®Google Scholar
• David E, Sun SY, Waller EK, The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 2005;106(13):4322-9
   PubMed Web of Science ®Google Scholar
• Liu G, Marrinan CH, Taylor SA, Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336). Anticancer Drugs 2007;18(8):923-31
   PubMed Web of Science ®Google Scholar
• Niessner H, Beck D, Sinnberg T, The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. J Invest Dermatol 2011;131(2):468-79
   PubMed Web of Science ®Google Scholar
• Wang E, Casciano CN, Clement RP, Johnson WW. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res 2001;61(20):7525-9
   PubMed Web of Science ®Google Scholar
• Han JY, Oh SH, Morgillo F, Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 2005;97(17):1272-86
   PubMed Web of Science ®Google Scholar
• Takada Y, Khuri FR, Aggarwal BB. Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis. J Biol Chem 2004;279(25):26287-99
   PubMed Web of Science ®Google Scholar
• Chun KH, Lee HY, Hassan K, Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res 2003;63(16):4796-800
   PubMed Web of Science ®Google Scholar
• Sun SY, Zhou Z, Wang R, The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt. Cancer Biol Ther 2004;3(11):1092-8; discussion 9-101
   PubMed Web of Science ®Google Scholar
• Schafer-Hales K, Iaconelli J, Snyder JP, Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther 2007;6(4):1317-28
   PubMed Web of Science ®Google Scholar
• Liu A, Du W, Liu JP, RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol 2000;20(16):6105-13
   PubMed Web of Science ®Google Scholar
• Basso AD, Mirza A, Liu G, The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J Biol Chem 2005;280(35):31101-8
   PubMed Web of Science ®Google Scholar
• Ren H, Tai SK, Khuri F, Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells. Cancer Res 2005;65(13):5841-7
   PubMed Web of Science ®Google Scholar
• Oh SH, Jin Q, Kim ES, Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression. Clin Cancer Res 2008;14(5):1581-9
   PubMed Web of Science ®Google Scholar
• Bruzek LM, Poynter JN, Kaufmann SH, Adjei AA. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2- b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336). Mol Pharmacol 2005;68(2):477-86
   PubMed Web of Science ®Google Scholar
• Capell BC, Erdos MR, Madigan JP, Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci USA 2005;102(36):12879-84
   PubMed Web of Science ®Google Scholar
• Reichert A, Heisterkamp N, Daley GQ, Groffen J. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood 2001;97(5):1399-403
   PubMed Web of Science ®Google Scholar
• Shi B, Yaremko B, Hajian G, The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 2000;46(5):387-93
   PubMed Web of Science ®Google Scholar
• Awada A, Eskens FA, Piccart M, Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur J Cancer 2002;38(17):2272-8
   PubMed Web of Science ®Google Scholar
• Eskens FA, Awada A, Cutler DL, Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 2001;19(4):1167-75
   PubMed Web of Science ®Google Scholar
• Kieran MW, Packer RJ, Onar A, Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol 2007;25(21):3137-43
   PubMed Web of Science ®Google Scholar
• Zhu Y, Statkevich P, Cutler DL. Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses. Int J Clin Pharmacol Ther 2007;45(10):539-47
   PubMed Web of Science ®Google Scholar
• Ghosal A, Chowdhury SK, Tong W, Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab Dispos 2006;34(4):628-35
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Amado R, Prager D, Phase I and clinical pharmacokinetic trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancer. Proc Am Soc Clin Oncol 2000;185a:abstract 717
   Google Scholar
• Theodore C, Geoffrois L, Vermorken JB, Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer 2005;41(8):1150-7
   PubMed Web of Science ®Google Scholar
• Khuri FR, Glisson BS, Kim ES, Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 2004;10(9):2968-76
   PubMed Web of Science ®Google Scholar
• Ready NE, Lipton A, Zhu Y, Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors. Clin Cancer Res 2007;13(2 Pt 1):576-83
   PubMed Web of Science ®Google Scholar
• Chow LQ, Eckhardt SG, O'Bryant CL, A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2008;62(4):631-46
   PubMed Web of Science ®Google Scholar
• Cortes J, Jabbour E, Daley GQ, Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 2007;110(6):1295-302
   PubMed Web of Science ®Google Scholar
• Castaneda C, Meadows KL, Truax R, Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;67(2):455-63
   PubMed Web of Science ®Google Scholar
• List AF, Deangelo D, O’Brien S, Phase I study of continuous oral administration of lonafarnib (Sarasar) in patients with advanced hematologic malignancies. Blood 2000;100:789a
   Web of Science ®Google Scholar
• Borthakur G, Kantarjian H, Daley G, Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 2006;106(2):346-52
   PubMed Web of Science ®Google Scholar
• Kies MS, Clayman GL, El-Naggar A, Induction therapy with SCH 66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of the head and neck [abstract]. Proc Ann Meet Am Soc Clin Oncol 2001;20:896
   Google Scholar
• Desjardins A, Reardon DA, Peters KB, A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. J Neurooncol 2011;105(3):601-6
   PubMed Web of Science ®Google Scholar
• Kauh J, Chanel-Vos C, Escuin D, Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. Cancer 2011;117(17):4049-59
   PubMed Web of Science ®Google Scholar
• Lersch C VCE, Amado R, Ehninger G, Randomized Phase II Study of SCH 66336 and Gemcitabine in the Treatment of Metastatic Adenocarcinoma of the Pancreas. Proceedings of the American Society of Clinical Oncology Annual Meeting; 2001
   Google Scholar
• Sharma S, Kemeny N, Kelsen DP, A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol 2002;13(7):1067-71
   PubMed Web of Science ®Google Scholar
• Ravoet C, Mineur P, Robin V, Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ann Hematol 2008;87(11):881-5
   PubMed Web of Science ®Google Scholar
• Feldman E, Cortes J, Holyoak T, Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome. Blood 2003;102:421a
   PubMedGoogle Scholar
• Hanrahan EO, Kies MS, Glisson BS, A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol 2009;32(3):274-9
   PubMed Web of Science ®Google Scholar
• Kim ES, Kies MS, Fossella FV, Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 2005;104(3):561-9
   PubMed Web of Science ®Google Scholar
• Blumenschein G, Ludwig C, Thomas G, A randomized Phase III trial comparing lonafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) [abstract O-082]. Proceedings from the 11th World Conference on Lung Cancer; Barcelona, Spain; 2005
   Google Scholar
• Glynn MW, Glover TW. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet 2005;14(20):2959-69
   PubMed Web of Science ®Google Scholar
• Buresh A, Perentesis J, Rimsza L, Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia. Leukemia 2005;19(2):308-10
   PubMed Web of Science ®Google Scholar
• Raponi M, Lancet JE, Fan H, A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008;111:2589-96
   PubMed Web of Science ®Google Scholar